PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Targeted therapy - Market size and forecast 2018-2023 • Chemotherapy - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY TYPE • Adenocarcinoma • Squamous cell carcinoma PART 10: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bristol-Myers Squibb Company • Eli Lilly and Company • F. Hoffmann-La Roche Ltd • Merck & Co., Inc. • Sanofi PART 16: APPENDIX • Research methodology • List of abbreviations PART 17: EXPLORE TECHNAVIO   Exhibit 01: Global oncology therapeutics market Exhibit 02: Segments of global oncology therapeutics market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Pipeline molecules for esophageal cancer Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Targeted therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Targeted therapy - Year-over-year growth 2019-2023 (%) Exhibit 22: Chemotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Chemotherapy - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by product Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 31: Europe - Year-over-year growth 2019-2023 (%) Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Asia - Year-over-year growth 2019-2023 (%) Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 35: ROW - Year-over-year growth 2019-2023 (%) Exhibit 36: Key leading countries Exhibit 37: Market opportunity Exhibit 38: Impact of drivers and challenges Exhibit 39: Vendor landscape Exhibit 40: Landscape disruption Exhibit 41: Vendors covered Exhibit 42: Vendor classification Exhibit 43: Market positioning of vendors Exhibit 44: Bristol-Myers Squibb Company - Vendor overview Exhibit 45: Bristol-Myers Squibb Company - Business segments Exhibit 46: Bristol-Myers Squibb Company - Organizational developments Exhibit 47: Bristol-Myers Squibb Company - Geographic focus Exhibit 48: Bristol-Myers Squibb Company - Key offerings Exhibit 49: Eli Lilly and Company - Vendor overview Exhibit 50: Eli Lilly and Company - Business segments Exhibit 51: Eli Lilly and Company - Organizational developments Exhibit 52: Eli Lilly and Company - Geographic focus Exhibit 53: Eli Lilly and Company - Segment focus Exhibit 54: Eli Lilly and Company - Key offerings Exhibit 55: F. Hoffmann-La Roche Ltd - Vendor overview Exhibit 56: F. Hoffmann-La Roche Ltd - Business segments Exhibit 57: F. Hoffmann-La Roche Ltd - Organizational developments Exhibit 58: F. Hoffmann-La Roche Ltd - Geographic focus Exhibit 59: F. Hoffmann-La Roche Ltd - Segment focus Exhibit 60: F. Hoffmann-La Roche Ltd - Key offerings Exhibit 61: Merck & Co., Inc. - Vendor overview Exhibit 62: Merck & Co., Inc. - Business segments Exhibit 63: Merck & Co., Inc. - Organizational developments Exhibit 64: Merck & Co., Inc. - Geographic focus Exhibit 65: Merck & Co., Inc. - Segment focus Exhibit 66: Merck & Co., Inc. - Key offerings Exhibit 67: Sanofi - Vendor overview Exhibit 68: Sanofi - Business segments Exhibit 69: Sanofi - Organizational developments Exhibit 70: Sanofi - Geographic focus Exhibit 71: Sanofi - Segment focus Exhibit 72: Sanofi - Key offerings Exhibit 73: Validation techniques employed for market sizing

Bristol-Myers Squibb Company Eli Lilly and Company F. Hoffmann-La Roche Ltd Merck & Co., Inc. Sanofi